Skip to main content

Table 3 Surfactant therapy and survival rate by GA or BW strata of RDS-related NRF

From: Outcome of neonatal hypoxemic respiratory failure: a livebirth population-based retrospective survey

 

GA, weeks

25–27

28–31

32–33

34–36

37–38

39–42

N

36

115

56

53

12

15

Male

22 (61.1)

66 (57.4)

33 (58.9)

30 (56.6)

9 (75.0)

13 (86.7)

BW, mean ± SD, g

1050 ± 179

1429 ± 296

1941 ± 351

2372 ± 557

2873 ± 522

3215 ± 763

Survival

17 (47.2)

83 (72.2)

50 (89.3)

50 (94.3)

11 (91.7)

13 (86.7)

Surfactant

29 (80.6)

87 (75.7)

35 (62.5)

29 (54.7)

7 (58.3)

8 (53.3)

Non-surfactant

7 (19.4)

28 (24.3)

21 (37.5)

24 (45.3)

5 (41.7)

7 (46.7)

Survival with surfactant

16 (55.2)

72 (82.8)

31 (88.6)

27 (93.1)

6 (85.7)

7 (87.5)

Survival without surfactant

1 (14.3)

11 (39.3)***

19 (90.5)

23 (95.8)

5 (100)

6 (85.7)

Difference, %a

40.9

43.5

−1.9

−2.7

−14.3

1.8

Numbers needed to treatb

2.4

2.3

56

 

BW, g

 

< 1000

1000–1499

1500–2499

2500–3999

≥4000

Total

N

20

98

113

54

2

287

Male

6 (30.0)

58 (59.8)

64 (56.6)

44 (81.5)

1 (50.0)

174 (60.3)

GA, mean ± SD, weeks

27.6 ± 1.8

29.5 ± 2.1

32.5 ± 1.9

36.9 ± 2.2

37.1 ± 3.0

32.0 ± 3.5

Survival

6 (30.0)

64 (65.3)

103 (91.2)

49 (90.7)

2 (100)

224 (78.0)

Surfactant

16 (80.0)

75 (76.5)

73 (64.6)

31 (57.4)

0

195 (67.9)

Non-surfactant

4 (20.0)

23 (23.5)

40 (35.4)

23 (42.6)

2 (100)

92 (32.1)

Survival with surfactant

6 (37.5)

55 (73.3)

70 (95.9)

28 (90.3)

2 (100)

159 (81.5)

Survival without surfactant

0

9 (39.1)**

33 (82.5)*

21 (91.3)

2 (100)

65 (70.7)*

Difference, %a

37.5

34.2

13.4

−1.0

0

10.8

Numbers needed to treatb

2.9

2.9

7.5

9.3

  1. All values are presented as mean ± standard deviation (SD) or n (%) referring to total number in each sub-group. Chi-square test was used for statistical analysis of differences in survival rate between surfactant- and non-surfactant-treated sub-groups
  2. Abbreviations: BW Birthweight, GA Gestational age, RDS Respiratory distress syndrome, NRF Neonatal respiratory failure
  3. *P < 0.05, *P < 0.01, ***P < 0.001 vs. survival with surfactant
  4. aThe attributable (absolute) risk of death rate (difference in percentile) between surfactant and non-surfactant treated sub-groups
  5. bEstimated by reciprocal (reverse ratio) of attributable risk difference multiplied by 100 for surfactant benefit